الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
Background: Glucagon-like peptide-1 (GLP-1), one of incretin hormones, can increase insulin sensitivity and regulate glucose homeostasis. Glp-1 agonisms are currently used widely in the treatment of type 2 diabetes (T2DM) which shares many patho-physiological events with non-Alcoholic Fatty Liver Disease (NAFLD). Recent studies suggest GLP-1 analogues as a new therapeutic agents against NAFLD.
Objectives: Studying GLP-1 secretion in diabetic and non-diabetic non-Alcoholic Fatty Liver Disease (NAFLD).
Patient & method: the study included 25 subjects with NAFLD, 25 subjects with T2DM + NAFLD and 25 subjects as controls. Glucose stimulated GLP-1 was measured for each subject.
Results: Controls exhibited a higher GLP-1 level (936.520 ± 149.380) compared with the remaining two groups (P < 0.001): (577.680 ± 161.681) in the non-diabetic NAFLD group and (485.520 ± 145.430) in diabetic NAFLD group. There was no significant difference in GLP-1 neither between diabetic and non- diabetic NAFLD groups.
Conclusion: Glucose-induced GLP-1 secretion is deficient in patients with NAFLD with and without T2DM. This pathophysiologic finding supports the evaluation of GLP-1 analogues for the treatment of NAFLD.